Globus Medical, Inc. (GMED) Financial Ratios
16 years of historical data (2010–2025) · Healthcare · Medical - Devices
EV/EBITDA
↓
17.12
↓-31% vs avg
5yr avg: 24.68
30Y Low5.7·High36.4
P/FCF
↓
18.13
↓-53% vs avg
5yr avg: 38.51
30Y Low18.3·High73.0
P/B Ratio
↓
2.37
↓-22% vs avg
5yr avg: 3.06
30Y Low1.5·High4.4
ROE
↑
12.3%
↓+58% vs avg
5yr avg: 7.8%
30Y Low3%·High24%
Debt/EBITDA
↑
0.20
↓-77% vs avg
5yr avg: 0.84
30Y Low0.0·High1.9
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
GMED Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Globus Medical, Inc. trades at 20.2x earnings, 63% below its 5-year average of 54.5x, sitting at the 7th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a discount of 9%. On a free-cash-flow basis, the stock trades at 18.1x P/FCF, 53% below the 5-year average of 38.5x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $10.7B | $12.0B | $11.4B | $6.1B | $7.6B | $7.5B | $6.6B | $6.0B | $4.4B | $4.0B | $2.4B |
| Enterprise Value | $10.3B | $11.6B | $11.2B | $6.2B | $7.5B | $7.3B | $6.3B | $5.8B | $4.2B | $3.9B | $2.3B |
| P/E Ratio → | 20.19 | 22.27 | 110.28 | 49.80 | 40.15 | 50.14 | 64.57 | 38.74 | 28.10 | 37.36 | 22.97 |
| P/S Ratio | 3.63 | 4.08 | 4.53 | 3.89 | 7.45 | 7.81 | 8.35 | 7.65 | 6.15 | 6.33 | 4.24 |
| P/B Ratio | 2.37 | 2.62 | 2.73 | 1.53 | 4.13 | 4.30 | 4.37 | 4.28 | 3.70 | 4.16 | 2.88 |
| P/FCF | 18.13 | 20.35 | 28.14 | 36.97 | 73.01 | 34.10 | 48.73 | 59.33 | 35.96 | 37.17 | 18.27 |
| P/OCF | 14.17 | 15.90 | 21.90 | 25.09 | 42.72 | 27.08 | 33.13 | 34.92 | 24.14 | 25.22 | 13.92 |
P/E links to full P/E history page with 30-year chart
GMED EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Globus Medical, Inc.'s enterprise value stands at 17.1x EBITDA, 31% below its 5-year average of 24.7x. The Healthcare sector median is 14.2x, placing the stock at a 20% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.94 | 4.43 | 3.93 | 7.31 | 7.61 | 8.04 | 7.40 | 5.95 | 6.14 | 4.12 |
| EV / EBITDA | 17.12 | 19.29 | 26.56 | 22.17 | 25.25 | 30.14 | 36.41 | 25.85 | 20.12 | 19.15 | 12.05 |
| EV / EBIT | 21.40 | 18.98 | 50.78 | 30.53 | 31.66 | 37.40 | 54.96 | 32.87 | 24.00 | 23.91 | 15.08 |
| EV / FCF | — | 19.66 | 27.53 | 37.29 | 71.62 | 33.22 | 46.96 | 57.40 | 34.81 | 36.07 | 17.75 |
GMED Profitability
Margins and return-on-capital ratios measuring operating efficiency
Globus Medical, Inc. earns an operating margin of 16.3%. Operating margins have expanded from 8.5% to 16.3% over the past 3 years, signaling improving operational efficiency. ROE of 12.3% is modest. ROIC of 8.9% represents adequate returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 67.4% | 67.4% | 58.9% | 65.1% | 74.2% | 75.0% | 72.4% | 77.1% | 77.6% | 76.3% | 76.1% |
| Operating Margin | 16.3% | 16.3% | 6.6% | 8.5% | 22.3% | 17.9% | 14.1% | 21.9% | 23.7% | 25.4% | 27.3% |
| Net Profit Margin | 18.3% | 18.3% | 4.1% | 7.8% | 18.6% | 15.6% | 13.0% | 19.8% | 21.9% | 16.9% | 18.5% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 12.3% | 12.3% | 2.5% | 4.2% | 10.6% | 9.2% | 7.0% | 12.0% | 14.5% | 11.9% | 13.5% |
| ROA | 10.2% | 10.2% | 2.0% | 3.4% | 9.4% | 8.2% | 6.4% | 11.0% | 13.2% | 10.7% | 11.8% |
| ROIC | 8.9% | 8.9% | 3.1% | 3.5% | 10.5% | 9.2% | 6.8% | 11.5% | 13.4% | 15.0% | 16.3% |
| ROCE | 10.4% | 10.4% | 3.7% | 4.0% | 12.2% | 10.2% | 7.5% | 13.1% | 15.5% | 17.7% | 19.3% |
GMED Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Globus Medical, Inc. carries a Debt/EBITDA ratio of 0.2x, which is very conservative (94% below the sector average of 3.2x). The company holds a net cash position — cash of $526M exceeds total debt of $119M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.13 | 0.13 | 0.00 | — | — | — | — | — | — |
| Debt / EBITDA | 0.20 | 0.20 | 1.28 | 1.87 | 0.02 | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.09 | -0.06 | 0.01 | -0.08 | -0.11 | -0.16 | -0.14 | -0.12 | -0.12 | -0.08 |
| Net Debt / EBITDA | -0.68 | -0.68 | -0.59 | 0.19 | -0.49 | -0.80 | -1.37 | -0.87 | -0.66 | -0.58 | -0.35 |
| Debt / FCF | — | -0.69 | -0.61 | 0.32 | -1.38 | -0.88 | -1.77 | -1.93 | -1.15 | -1.10 | -0.51 |
| Interest Coverage | — | — | 52.45 | — | — | — | — | — | — | — | — |
Net cash position: cash ($526M) exceeds total debt ($119M)
GMED Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Globus Medical, Inc.'s current ratio of 4.26x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 2.74x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 4.88x to 4.26x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.26 | 4.26 | 2.54 | 4.88 | 6.18 | 6.17 | 6.80 | 6.17 | 6.56 | 6.67 | 6.43 |
| Quick Ratio | 2.74 | 2.74 | 1.77 | 2.72 | 4.30 | 4.48 | 4.91 | 4.41 | 5.20 | 5.50 | 5.02 |
| Cash Ratio | 1.12 | 1.12 | 1.04 | 1.32 | 2.80 | 3.16 | 3.53 | 2.80 | 3.53 | 4.02 | 3.63 |
| Asset Turnover | — | 0.55 | 0.48 | 0.31 | 0.49 | 0.49 | 0.47 | 0.51 | 0.55 | 0.59 | 0.61 |
| Inventory Turnover | 1.26 | 1.26 | 1.57 | 0.65 | 0.88 | 1.01 | 0.95 | 0.92 | 1.21 | 1.39 | 1.20 |
| Days Sales Outstanding | — | 84.32 | 83.79 | 117.49 | 77.55 | 63.11 | 68.51 | 75.49 | 73.90 | 72.92 | 61.99 |
GMED Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Globus Medical, Inc. returns 2.8% to shareholders annually primarily through share buybacks. The earnings yield of 5.0% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 5.0% | 4.5% | 0.9% | 2.0% | 2.5% | 2.0% | 1.5% | 2.6% | 3.6% | 2.7% | 4.4% |
| FCF Yield | 5.5% | 4.9% | 3.6% | 2.7% | 1.4% | 2.9% | 2.1% | 1.7% | 2.8% | 2.7% | 5.5% |
| Buyback Yield | 2.8% | 2.5% | 0.8% | 3.7% | 1.9% | 0.0% | 1.6% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 2.8% | 2.5% | 0.8% | 3.7% | 1.9% | 0.0% | 1.6% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $137M | $138M | $115M | $103M | $104M | $101M | $102M | $101M | $98M | $96M |
Peer Comparison
Compare GMED with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 GMEDYou | $11B | 20.2 | 17.1 | 18.1 | 67.4% | 16.3% | 12.3% | 8.9% | 0.2 |
 SYK | $117B | 36.3 | 21.0 | 27.2 | 64.0% | 19.5% | 15.1% | 11.4% | 2.4 |
 ZBH | $17B | 24.5 | 9.8 | 11.6 | 61.6% | 16.5% | 5.6% | 5.4% | 3.1 |
 ATEC | $1B | -8.9 | 4030.4 | 466.2 | 69.6% | -10.7% | -630.7% | -12.6% | 1425.2 |
 XTNT | $61M | 14.5 | 5.8 | 6.0 | 62.9% | 5.4% | 10.6% | 8.1% | 2.3 |
 MDT | $102B | 22.0 | 14.5 | 19.6 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 |
 BSX | $66B | 22.9 | 20.4 | 18.0 | 69.0% | 19.8% | 12.4% | 8.8% | 3.3 |
 HOLX | $17B | 30.5 | 17.4 | 18.4 | 61.0% | 17.4% | 11.1% | 9.4% | 2.6 |
 NVCR | $2B | -11.2 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 ISRG | $143B | 51.2 | 38.7 | 57.5 | 66.0% | 29.3% | 16.6% | 15.0% | 0.1 |
 MMSI | $4B | 31.2 | 13.8 | 18.4 | 48.7% | 12.2% | 8.7% | 7.2% | 2.8 |
| Healthcare Median | — | 22.1 | 14.2 | 18.4 | 63.9% | -4.4% | -33.2% | -11.7% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 16 years · Updated daily
Consensus-Based Analysis Tools
Full Stock Analysis
Deep dive into GMED consensus models and risk factors.
View Analysis
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
GMED — Frequently Asked Questions
Quick answers to the most common questions about buying GMED stock.
What is Globus Medical, Inc.'s P/E ratio?
Globus Medical, Inc.'s current P/E ratio is 20.2x. The historical average is 39.5x. This places it at the 7th percentile of its historical range.
What is Globus Medical, Inc.'s EV/EBITDA?
Globus Medical, Inc.'s current EV/EBITDA is 17.1x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 20.3x.
What is Globus Medical, Inc.'s ROE?
Globus Medical, Inc.'s return on equity (ROE) is 12.3%. The historical average is 13.6%.
Is GMED stock overvalued?
Based on historical data, Globus Medical, Inc. is trading at a P/E of 20.2x. This is at the 7th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Globus Medical, Inc.'s profit margins?
Globus Medical, Inc. has 67.4% gross margin and 16.3% operating margin. Operating margin between 10-20% is typical for established companies.
How much debt does Globus Medical, Inc. have?
Globus Medical, Inc.'s Debt/EBITDA ratio is 0.2x, indicating low leverage. A ratio below 2x is generally considered financially healthy.